K. Fizazi

2463P Efficacy and safety of rucaparib in patients with BRCA-mutated metastatic castration-resistant prostate cancer after crossover from physician’s choice therapy on TRITON3

C.J. Ryan, K. Fizazi, Alan Haruo Bryce, N. Alimohamed et autres

us, fr, it, es, gb (code pays fourni par la source)

2428P Time to response with talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2

N. Agarwal, A.A. Azad, S. Zschäbitz, André Poisl Fay et autres

es, us, au, de, br, ca, no, it, nz, gb, fr (code pays fourni par la source)

2429P Machine learning (ML) prediction of anemia in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA)

U. De Giorgi, Chunlong Zhang, Bo Zhou, Stephen E. Schachterle et autres

it, us, fr, au (code pays fourni par la source)

LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

S.T. Tagawa, O. Sartor, J.M. Piulats, F. Saad et autres

us, gb, es, ca, fr, at, de, kr, tw, ch (code pays fourni par la source)

P103 Assessment of the impact of talazoparib dose reductions on the efficacy of combined talazoparib and enzalutamide treatment in patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) in the TALAPRO-2 (TP-2) study

U. De Giorgi, N. Agarwal, K. Fizazi, J. Carles et autres

Patient (pt) reported pain and health-related quality of life (HRQoL) by genomic loss of heterozygosity (gLOH) status in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1

F. Saad, A. Stenzl, N. Mehra, A. Stirling et autres